These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 28625639)
1. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. Tchekmedyian N; Mudad R; Blanco FF; Raymond VM; Garst J; Erlander MG; Haura E; Berz D Lung Cancer; 2017 Jun; 108():22-28. PubMed ID: 28625639 [TBL] [Abstract][Full Text] [Related]
2. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis. Sands J; Li Q; Hornberger J Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213 [TBL] [Abstract][Full Text] [Related]
3. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078 [TBL] [Abstract][Full Text] [Related]
4. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Chen S; Zhao J; Cui L; Liu Y Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867 [TBL] [Abstract][Full Text] [Related]
5. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
6. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer. Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342 [TBL] [Abstract][Full Text] [Related]
7. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209 [TBL] [Abstract][Full Text] [Related]
8. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
9. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581 [TBL] [Abstract][Full Text] [Related]
10. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA. Ikushima H; Sakatani T; Usui K Oncology; 2020; 98(1):23-28. PubMed ID: 31494653 [TBL] [Abstract][Full Text] [Related]
11. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448 [TBL] [Abstract][Full Text] [Related]
12. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031 [TBL] [Abstract][Full Text] [Related]
13. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500 [TBL] [Abstract][Full Text] [Related]
14. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111 [TBL] [Abstract][Full Text] [Related]
15. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance. He J; Tan W; Tang X; Ma J Pathol Oncol Res; 2017 Apr; 23(2):307-315. PubMed ID: 27511219 [TBL] [Abstract][Full Text] [Related]
16. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. Diao Z; Han Y; Zhang R; Li J Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933 [TBL] [Abstract][Full Text] [Related]
18. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985 [TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer. He J; Tan W; Ma J Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294 [TBL] [Abstract][Full Text] [Related]
20. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]